STAT+: Pharmalittle: We’re reading about an FDA commish nominee, mRNA cancer vaccine results, and more

President Trump is expected to nominate Heidi Overton, the White House's deputy director of domestic policy, to serve as the next commissioner of the U.S. Food and Drug Administration (FDA), according to STAT. Overton, who has been a prominent health policy voice during Trump's second term, will face scrutiny from a U.S. Senate panel before securing the position. As the deputy director of domestic policy, Overton has worked closely with the U.S. Health and Human Services Department.

A late-stage clinical trial of a personalized mRNA cancer vaccine, developed by Merck and Moderna, has shown promising results. When combined with an existing treatment, the vaccine slowed the return of melanoma and its spread to other parts of the body, according to STAT. If the results hold true, the vaccine could revolutionize oncology and provide new hope and potentially longer lives for patients.

The vaccine's development further demonstrates the potential of mRNA as a platform for both traditional vaccines and therapeutics.

An approval of the treatment would not only benefit Moderna's mRNA platform but also be a significant achievement for the company, which has become a political lightning rod due to its mRNA-based COVID-19 vaccine. The FDA commish nominee, Overton's appointment, and the groundbreaking vaccine trial results all contribute to the ongoing discourse surrounding healthcare policy, innovation, and the future of medicine.